[Efficacy and safety of cefditoren pivoxil in treatment of respiratory infections, a clinical study].

Abstract

OBJECTIVE:

To evaluate the efficacy and safety of cefditoren pivoxil in treatment of respiratory infections.

METHODS:

199 cases of respiratory infection confirmed by etiological and clinical examinations were treated with cefditoren pivoxil tablets taken orally. Therapeutic evaluation was conducted among 196 cases and safety evaluation was conducted among 199 cases.

RESULTS:

The total effective rate was 94.9%, and the causative bacteria -elimination rate was 96.7%. Clinical adverse events, including moderate diarrhea, mild nausea and vomiting, and stomach discomfort, were seen in 9 cases with an incidence rate of 4.5%. Laboratory adverse events, including increase of with an incidence rate of 3.5%.

CONCLUSION:

Cefditoren pivoxil is effective and safe in treatment of mild and moderate respiratory infections. The resistance rate to cefditoren pivoxil of pathogens of respiratory infections and the efficacy of cefditoren pivoxil show no difference from those tested 7 years ago.

• Authors: Jia-Tai Li, Lei Gao, Feng Xue, Feng-Lan Hao, Qi Wang, Bai-Qiang Cai, Chun-Lan Gan, You-Ning Liu, Bing-Xiang Yu, Li-Xian He, Bi-Jie Hu, Xue-Hua Chen, Jing-Chuan Zheng, Yun-Song Yu, Fang-Fang Lu, De-Rong Liang, Yong-Ning Cai, Jian Kang, Ling-Fei Kong, Zheng-Lun Xiao, Jin-Ping Zheng, Jie Liu, Wei-Xing Yang, Jing Zhou
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 83 Issue 5 Pg. 391-4 (Mar 10 2003) ISSN: 0376-2491 [Print] China
• PMID: 12820915 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• cefditoren pivoxil

Topics

• Adolescent
• Adult
• Aged
• Anti-Bacterial Agents (adverse effects, pharmacology, therapeutic use)
• Bacterial Infections (drug therapy, microbiology)
• Cephalosporins (adverse effects, pharmacology, therapeutic use)
• Female
• Haemophilus influenzae (drug effects)
• Humans
• Male
• Middle Aged
• Pneumonia, Bacterial (drug therapy)
• Product Surveillance, Postmarketing
• Respiratory Tract Infections (drug therapy, microbiology)
• Streptococcus pneumoniae (drug effects)